Clinical trial
Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study
NCT07927764 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Predictive Factors of Long-term Survivor (LTS) of Patients With Recurrent or Metastatic, Radio-iodine Resistant Differentiated Thyroid Cancer (RRDTC) After Lenvatinib: a Multicenter Study
- Lead sponsor
- IRCCS San Raffaele
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- December 31, 2026
- Completion date
- June 30, 2027
- Enrollment
- 65 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
head and neck cancer
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Median Duration of Overall Response (DOR) in a Real-World Setting
Assessment of the median duration of overall response (DOR) in a real-world setting in patients with locally advanced or metastatic radioiodine-refractory differentiated thyroid cancer who achieved stable disease (SD), complete response (CR), or partial response (PR) following treatment with lenvatinib.
Lead sponsor's other trials
IRCCS San Raffaele, most recent start first.
+519 more trials See the organization page
Similar trials
Same condition (Head and Neck Neoplasms) and phase, most recent start first.
+514 more trials See the condition page